Argent Trust Co boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.8% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 150,560 shares of the company’s stock after acquiring an additional 5,566 shares during the period. Johnson & Johnson accounts for 1.7% of Argent Trust Co’s holdings, making the stock its 4th biggest position. Argent Trust Co’s holdings in Johnson & Johnson were worth $24,745,000 at the end of the most recent quarter.
Other large investors have also recently bought and sold shares of the company. Cypress Point Wealth Management LLC purchased a new stake in Johnson & Johnson during the fourth quarter valued at approximately $25,000. Klaas Financial Asset Advisors LLC acquired a new position in Johnson & Johnson during the 4th quarter valued at approximately $36,000. NuWave Investment Management LLC acquired a new position in Johnson & Johnson during the 1st quarter valued at approximately $39,000. JCIC Asset Management Inc. increased its stake in Johnson & Johnson by 950.0% during the 4th quarter. JCIC Asset Management Inc. now owns 315 shares of the company’s stock valued at $50,000 after purchasing an additional 285 shares in the last quarter. Finally, CBIZ Investment Advisory Services LLC increased its stake in shares of Johnson & Johnson by 47.4% in the fourth quarter. CBIZ Investment Advisory Services LLC now owns 588 shares of the company’s stock worth $59,000 after acquiring an additional 189 shares during the period. 66.74% of the stock is owned by institutional investors.
Several analysts recently commented on JNJ shares. Credit Suisse Group set a $193.00 price target on shares of Johnson & Johnson and gave the company a “buy” rating in a research report on Monday. Morgan Stanley started coverage on shares of Johnson & Johnson in a research report on Friday, May 28th. They set an “overweight” rating and a $187.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $182.45.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Monday, April 19th. The company reported $2.59 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.34 by $0.25. The firm had revenue of $22.30 billion for the quarter, compared to the consensus estimate of $22 billion. Johnson & Johnson had a net margin of 17.95% and a return on equity of 34.62%. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period last year, the firm posted $2.30 earnings per share. Sell-side analysts forecast that Johnson & Johnson will post 9.51 EPS for the current year.
The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 8th. Stockholders of record on Tuesday, May 25th were paid a $1.06 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.01. This represents a $4.24 annualized dividend and a dividend yield of 2.58%. The ex-dividend date of this dividend was Monday, May 24th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 52.80%.
About Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
Read More: What are the most popular ETFs
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.